Holen Sie sich die Stockscreener-App
5.88
0.84%
-0.05
Handel nachbörslich:
5.98
0.10
+1.70%
Schlusskurs vom Vortag:
$5.93
Offen:
$5.5
24-Stunden-Volumen:
1.01M
Relative Volume:
0.98
Marktkapitalisierung:
$515.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-1.7755
EPS:
-3.3117
Netto-Cashflow:
$-8.40M
1W Leistung:
-12.63%
1M Leistung:
-37.04%
6M Leistung:
-52.77%
1J Leistung:
-70.98%
1-Tages-Spanne:
$5.35
$6.135
1-Wochen-Bereich:
$5.35
$6.94
52-Wochen-Spanne:
$5.35
$21.72
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
5.88 | 515.62M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Immunome stock hits 52-week low at $5.5 amid market challenges - Investing.com
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Immunome's Latest Cancer Therapy Progress: Key Investor Presentation Coming to Needham Conference - Stock Titan
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
Immunome's Latest Growth Move: 5 Key Hires Secure Significant Equity Package - Stock Titan
Clay Siegall Bought 20% More Shares In Immunome - simplywall.st
Immunome stock hits 52-week low at $6.94 amid market challenges By Investing.com - Investing.com South Africa
Immunome stock hits 52-week low at $6.94 amid market challenges - Investing.com India
Immunome (NASDAQ:IMNM) Stock Price Up 4.4% After Insider Buying Activity - Defense World
Immunome (IMNM) Stock Climbs as Executives Increase Holdings - GuruFocus
Immunome CEO Clay Siegall buys $999k in stock By Investing.com - Investing.com Australia
Immunome director Jean Jacques Bienaime acquires $60,684 in stock - Investing.com
Immunome director Jean Jacques Bienaime acquires $60,684 in stock By Investing.com - Investing.com South Africa
Immunome CEO Clay Siegall buys $999k in stock - Investing.com India
Immunome stock rises after insider purchase (IMNM:NASDAQ) - Seeking Alpha
Immunome director Jean Jacques Bienaime purchases $57,470 in stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome CTO Philip Tsai purchases $103,566 in stock By Investing.com - Investing.com Canada
Immunome director Jean Jacques Bienaime purchases $57,470 in stock - Investing.com
Immunome CTO Philip Tsai purchases $103,566 in stock - Investing.com
Bank of New York Mellon Corp Has $1.31 Million Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wedbush Has Positive Estimate for Immunome Q1 Earnings - Defense World
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush - MarketBeat
Immunome’s (IMNM) “Outperform” Rating Reiterated at Wedbush - Defense World
Guggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock Price - Defense World
Stephens Reiterates Overweight Rating for Immunome (NASDAQ:IMNM) - Defense World
Trading (IMNM) With Integrated Risk Controls - news.stocktradersdaily.com
Immunome Full Year 2024 Earnings: Misses Expectations - Yahoo
Immunome’s 2024 Financial Results and Pipeline Progress - TipRanks
Immunome stock target cut to $25 by Guggenheim - Investing.com Australia
Immunome (IMNM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Immunome earnings missed by $0.45, revenue fell short of estimates - Investing.com Canada
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Immunome 2024 Net Loss Narrows -March 19, 2025 at 05:07 pm EDT - Marketscreener.com
Immunome Inc. (IMNM) reports earnings - Quartz
Immunome Inc. SEC 10-K Report - TradingView
Immunome Reports Full Year 2024 Financial Results and Provides Business Update - The Bakersfield Californian
Immunome stock hits 52-week low at $8.37 amid market challenges - Investing.com Australia
Immunome stock hits 52-week low at $8.37 amid market challenges By Investing.com - Investing.com South Africa
With 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional owners - Yahoo
Immunome, Inc. (NASDAQ:IMNM) Receives $27.17 Average PT from Analysts - MarketBeat
Lifesci Capital Predicts Immunome FY2024 Earnings - Defense World
Q1 Earnings Forecast for Immunome Issued By Lifesci Capital - Defense World
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $27.17 - Defense World
Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital - Defense World
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):